881833-22-3

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[[[(4-chlorophenyl)methyl]amino]carbonyl]-, 1,1-dimethylethyl ester
• CAS NO: 881833-22-3
• Molecular Formula: C18H25ClN2O3
• Molecular Weight: 352.861
• Mol File: 881833-22-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[[[(4-chlorophenyl)methyl]amino]carbonyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[[[(4-chlorophenyl)methyl]amino]carbonyl]-, 1,1-dimethylethyl ester(881833-22-3)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[[[(4-chlorophenyl)methyl]amino]carbonyl]-, 1,1-dimethylethyl ester(881833-22-3)

Safety Data

• Hazardous Substances Data: 881833-22-3(Hazardous Substances Data)

Usage

Classification

Synthetic opioid, Schedule II controlled substance.

Use

Pain reliever and anesthetic.

Mechanism of action

Binds to the body's opioid receptors, producing pain relief and feelings of euphoria.

Risks

High potential for abuse and addiction, high risk of overdose and respiratory depression, especially when used improperly or in combination with other substances. Implicated in a significant number of overdose deaths due to its potent and fast-acting nature.

Upstream product

• 104-86-9 4-chlorobenzylamine 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 

Downstream Products

• 1144037-34-2 C₁₃H₁₇ClN₂O*ClH 
• 885274-77-1 C₁₃H₁₇ClN₂O 
• 881833-23-4 4-(N-(4-chlorobenzyl)aminomethyl)-1-t-butoxycarbonylpiperidine 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel piperidine-4- carboxamide derivatives as potent CCR5 inhibitors

Based on a putative 'Y shape' pharmacophore model of CCR5 inhibitors, a series of novel piperidine-4-carboxamide derivatives were designed and synthesized using a group-reverse strategy. Among synthesized target compounds, 16g (IC50 = 25.73 nM) and 16i (IC50 = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC50 = 25.43 nM) in calcium mobilization assay. Selected compounds were further tested for their antiviral activity in HIV-1 single cycle assay. Two compounds, 16g and 16i, displayed antiviral activity with IC 50 values of 73.01 nM and 94.10 nM, respectively. Additionally, the pharmacokinetic properties and inhibitory potency against hERG of 16g were evaluated, providing a foundation for ongoing optimization.

N-sulfonylpiperidine cannabinoid receptor 1 antagonists

The present application describes compounds according to Formula I, wherein R1, R2, R3, R4, X and Y are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. Finally, the present application describes methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents.